Breast Cancer – Benefits of Trodelvy in HR+/HER2-
סרטן שד - יתרונות עם טרודלבי ב HR+/HER2-

Breast Cancer – Benefits of Trodelvy in HR+/HER2-

Background The antibody-drug conjugate Trodelvy offers statistically and clinically significant benefits for patients with heavily pretreated HR+/HER2- breast cancer, according to results of the TROPiCS-02 study, recently presented. HR+/HER2- is…

Continue Reading Breast Cancer – Benefits of Trodelvy in HR+/HER2-